Antibiotic treatment with one single dose of gentamicin at admittance in addition to a β-lactam antibiotic in the treatment of community-acquired bloodstream infection with sepsis.
Acute Kidney Injury
/ chemically induced
Aged
Anti-Bacterial Agents
/ administration & dosage
Bacteremia
/ drug therapy
Bacteria
/ drug effects
Community-Acquired Infections
/ drug therapy
Drug Therapy, Combination
Female
Gentamicins
/ administration & dosage
Hospitalization
Humans
Male
Organ Dysfunction Scores
Retrospective Studies
Sepsis
/ drug therapy
beta-Lactams
/ administration & dosage
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
05
2019
accepted:
16
07
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
25
9
2020
Statut:
epublish
Résumé
Combination therapy in the treatment of sepsis, especially the value of combining a β-Lactam antibiotic with an aminoglycoside, has been discussed. This retrospective cohort study including patients with sepsis or septic shock aimed to investigate whether one single dose of gentamicin at admittance (SGA) added to β-Lactam antibiotic could result in a lower risk of mortality than β-Lactam monotherapy, without exposing the patient to the risk of nephrotoxicity. All patients with positive blood cultures were evaluated for participation (n = 1318). After retrospective medical chart review, a group of patients with community-acquired sepsis with positive blood cultures who received β-Lactam antibiotic with or without the addition of SGA (n = 399) were included for the analysis. Mean age was 74.6 yrs. (range 19-98) with 216 (54%) males. Sequential Organ Failure Assessment score (SOFA score) median was 3 (interquartile range [IQR] 2-5) and the median Charlson Comorbidity Index for the whole group was 2 (IQR 1-3). Sixty-seven (67) patients (17%) had septic shock. The 28-day mortality in the combination therapy group was 10% (20 of 197) and in the monotherapy group 22% (45 of 202), adjusted HR 3.5 (95% CI (1.9-6.2), p = < 0.001. No significant difference in incidence of acute kidney injury (AKI) was detected. This retrospective observational study including patients with community-acquired sepsis or septic shock and positive blood cultures, who meet Sepsis-3 criteria, shows that the addition of one single dose of gentamicin to β-lactam treatment at admittance was associated with a decreased risk of mortality and was not associated with AKI. This antibiotic regime may be an alternative to broad-spectrum antibiotic treatment of community-acquired sepsis. Further prospective studies are warranted to confirm these results.
Sections du résumé
BACKGROUND
Combination therapy in the treatment of sepsis, especially the value of combining a β-Lactam antibiotic with an aminoglycoside, has been discussed. This retrospective cohort study including patients with sepsis or septic shock aimed to investigate whether one single dose of gentamicin at admittance (SGA) added to β-Lactam antibiotic could result in a lower risk of mortality than β-Lactam monotherapy, without exposing the patient to the risk of nephrotoxicity.
METHODS AND FINDINGS
All patients with positive blood cultures were evaluated for participation (n = 1318). After retrospective medical chart review, a group of patients with community-acquired sepsis with positive blood cultures who received β-Lactam antibiotic with or without the addition of SGA (n = 399) were included for the analysis. Mean age was 74.6 yrs. (range 19-98) with 216 (54%) males. Sequential Organ Failure Assessment score (SOFA score) median was 3 (interquartile range [IQR] 2-5) and the median Charlson Comorbidity Index for the whole group was 2 (IQR 1-3). Sixty-seven (67) patients (17%) had septic shock. The 28-day mortality in the combination therapy group was 10% (20 of 197) and in the monotherapy group 22% (45 of 202), adjusted HR 3.5 (95% CI (1.9-6.2), p = < 0.001. No significant difference in incidence of acute kidney injury (AKI) was detected.
CONCLUSION
This retrospective observational study including patients with community-acquired sepsis or septic shock and positive blood cultures, who meet Sepsis-3 criteria, shows that the addition of one single dose of gentamicin to β-lactam treatment at admittance was associated with a decreased risk of mortality and was not associated with AKI. This antibiotic regime may be an alternative to broad-spectrum antibiotic treatment of community-acquired sepsis. Further prospective studies are warranted to confirm these results.
Identifiants
pubmed: 32730359
doi: 10.1371/journal.pone.0236864
pii: PONE-D-19-14144
pmc: PMC7392313
doi:
Substances chimiques
Anti-Bacterial Agents
0
Gentamicins
0
beta-Lactams
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0236864Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Microbiol Infect. 2008 Apr;14 Suppl 3:15-21
pubmed: 18318875
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Am J Med. 1986 Jun 30;80(6B):98-104
pubmed: 3524221
Clin Infect Dis. 2017 Jun 15;64(12):1731-1736
pubmed: 28329088
J R Soc Med. 1992 Sep;85(9):530-3
pubmed: 1433118
Crit Care Med. 2003 Feb;31(2):462-7
pubmed: 12576952
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Kidney Int. 2011 Jan;79(1):33-45
pubmed: 20861826
Am J Med. 1986 Jun 30;80(6B):126-37
pubmed: 3088998
Int J Antimicrob Agents. 2005 Aug;26(2):146-51
pubmed: 16024233
Antimicrob Agents Chemother. 2014 Dec;58(12):7468-74
pubmed: 25288085
Antimicrob Agents Chemother. 2010 Nov;54(11):4851-63
pubmed: 20733044
Int J Antimicrob Agents. 2009 Mar;33(3):201-5
pubmed: 18976888
Mitochondrion. 2011 Mar;11(2):237-45
pubmed: 21047563
J Infect Public Health. 2019 Sep - Oct;12(5):695-699
pubmed: 31000490
Clin Kidney J. 2013 Feb;6(1):8-14
pubmed: 27818745
PLoS One. 2014 Nov 06;9(11):e104475
pubmed: 25375775
JAMA. 2014 Apr 2;311(13):1308-16
pubmed: 24638143
Rev Infect Dis. 1982 Mar-Apr;4(2):282-93
pubmed: 7051231
J Antimicrob Chemother. 2011 Apr;66 Suppl 2:ii11-23
pubmed: 21398303
Clin Infect Dis. 2007 Sep 15;45(6):753-60
pubmed: 17712761
Scand J Infect Dis. 2003;35(1):40-6
pubmed: 12685883
J Antimicrob Chemother. 2009 Feb;63(2):246-51
pubmed: 19022778
Scand J Infect Dis. 2013 Mar;45(3):161-75
pubmed: 23270477
Open Forum Infect Dis. 2016 Dec 8;3(4):ofw207
pubmed: 27942538
J Infect Dis. 1979 Oct;140(4):639-41
pubmed: 390068
Int J Clin Pract. 2017 Mar;71(3-4):
pubmed: 28276182
J Infect Dis. 1984 Feb;149(2):257-63
pubmed: 6421944
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Am J Infect Control. 2011 Nov;39(9):e61-5
pubmed: 21835504
Lancet. 2017 Mar 25;389(10075):1238-1252
pubmed: 27887750
N Engl J Med. 2013 Aug 29;369(9):840-51
pubmed: 23984731
Infect Dis (Lond). 2016 Apr;48(4):274-280
pubmed: 26567531
Crit Care Med. 2013 Feb;41(2):580-637
pubmed: 23353941
Crit Care Med. 2010 Aug;38(8):1651-64
pubmed: 20562695
Emerg Med J. 2018 Jun;35(6):345-349
pubmed: 29467173
JAMA. 2016 Feb 23;315(8):775-87
pubmed: 26903336
Crit Care. 2010;14(2):R53
pubmed: 20370907
Crit Care Med. 2006 Jun;34(6):1589-96
pubmed: 16625125
Emerg Med J. 2016 Jan;33(1):37-41
pubmed: 25971890
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219
Respirology. 2015 Jul;20(5):813-8
pubmed: 25998684
Clin Microbiol Infect. 2015 Jul;21(7):649.e1-10
pubmed: 25882363
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Cochrane Database Syst Rev. 2014 Jan 07;(1):CD003344
pubmed: 24395715
Crit Care Med. 2014 Mar;42(3):625-31
pubmed: 24201173
BMC Public Health. 2018 Sep 15;18(1):1121
pubmed: 30219056
Crit Care Med. 2010 Sep;38(9):1773-85
pubmed: 20639750
Acad Emerg Med. 2014 Nov;21(11):1257-63
pubmed: 25377403